Literature DB >> 2286486

The effects of moderate exercise training on natural killer cells and acute upper respiratory tract infections.

D C Nieman1, S L Nehlsen-Cannarella, P A Markoff, A J Balk-Lamberton, H Yang, D B Chritton, J W Lee, K Arabatzis.   

Abstract

A randomly controlled 15-wk exercise training (ET) study (five 45-min sessions/wk, brisk walking at 60% heart rate reserve) with a group of 36 mildly obese, sedentary women was conducted to investigate the relationship between improvement in cardiorespiratory fitness, changes in natural killer (NK) cell number and activity, and acute upper respiratory tract infection (URI) symptomatology. The study was conducted using a 2 (exercise and nonexercise groups) x 3 (baseline, 6-, and 15-wk testing sessions) factorial design, with data analyzed using repeated measures ANOVA. No significant change in NK cell number occurred as a result of ET as measured by the CD16 and Leu-19 monoclonal antibodies. ET did have a significant effect on NK cell activity (E:T 50:1) especially during the initial 6-wk period [F(2.68) = 12.34, p less than 0.001]. Using data from daily logs kept by each subject, the exercise group was found to have significantly fewer URI symptom days/incident than the nonexercise group (3.6 +/- 0.7 vs 7.0 +/- 1.4 days, respectively, p = 0.049). Improvement in cardiorespiratory fitness was correlated significantly with a reduction in URI symptom days/incident (r = 0.37, p = 0.025) and a change in NK cell activity from baseline to six but not 15 wks (r = 0.35, p = 0.036). In summary, moderate ET is associated with elevated NK cell activity after six but not 15 weeks, and reduced URI symptomatology in comparison to a randomized, sedentary control group.

Entities:  

Mesh:

Year:  1990        PMID: 2286486     DOI: 10.1055/s-2007-1024839

Source DB:  PubMed          Journal:  Int J Sports Med        ISSN: 0172-4622            Impact factor:   3.118


  58 in total

1.  Change in perforin-positive peripheral blood lymphocyte (PBL) subpopulations following exercise.

Authors:  R Staats; S Balkow; S Sorichter; H Northoff; H Matthys; W Luttmann; A Berg; J C Virchow
Journal:  Clin Exp Immunol       Date:  2000-06       Impact factor: 4.330

2.  Effects of exercise and training on natural killer cell counts and cytolytic activity: a meta-analysis.

Authors:  R J Shephard; P N Shek
Journal:  Sports Med       Date:  1999-09       Impact factor: 11.136

Review 3.  Dairy products, meat and sports performance.

Authors:  Mikael Fogelholm
Journal:  Sports Med       Date:  2003       Impact factor: 11.136

4.  The effect of maximal exercise on the activity of neutrophil granulocytes in highly trained athletes in a moderate training period.

Authors:  V Hack; G Strobel; J P Rau; H Weicker
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1992

Review 5.  The effects of acute and chronic exercise of immunoglobulins.

Authors:  D C Nieman; S L Nehlsen-Cannarella
Journal:  Sports Med       Date:  1991-03       Impact factor: 11.136

6.  Psychosocial predictors of health status revisited.

Authors:  Marcelline Fusilier; Michael R Manning
Journal:  J Behav Med       Date:  2005-08

7.  Risk of upper respiratory tract infection in athletes: an epidemiologic and immunologic perspective.

Authors:  D C Nieman
Journal:  J Athl Train       Date:  1997-10       Impact factor: 2.860

8.  Energy restriction and exercise differentially enhance components of systemic and mucosal immunity in mice.

Authors:  Connie J Rogers; David Berrigan; David A Zaharoff; Kenneth W Hance; Arti C Patel; Susan N Perkins; Jeffrey Schlom; John W Greiner; Stephen D Hursting
Journal:  J Nutr       Date:  2008-01       Impact factor: 4.798

Review 9.  Exercise and the immune system. Natural killer cells, interleukins and related responses.

Authors:  R J Shephard; S Rhind; P N Shek
Journal:  Sports Med       Date:  1994-11       Impact factor: 11.136

10.  Exercise and respiratory tract viral infections.

Authors:  Stephen A Martin; Brandt D Pence; Jeffrey A Woods
Journal:  Exerc Sport Sci Rev       Date:  2009-10       Impact factor: 6.230

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.